For research use only. Not for therapeutic Use.
PMPA (2-(Phosphonomethyl)pentanedioic acid)（Cat No.:R063627）is a selective NAALADase inhibitor, targeting N-acetylated α-linked acidic dipeptidase (NAALADase), also known as glutamate carboxypeptidase II. By inhibiting this enzyme, PMPA prevents the breakdown of N-acetylaspartylglutamate (NAAG), a neuropeptide that modulates glutamate signaling. This inhibition reduces excess glutamate levels, which can protect against excitotoxicity—a factor in neurodegenerative diseases like ALS, stroke, and Alzheimer’s disease. PMPA’s action makes it a valuable compound for studying glutamatergic signaling, offering potential for therapies aimed at neuroprotection and managing glutamate-mediated neurotoxicity.
| Catalog Number | R063627 |
| CAS Number | 173039-10-6 |
| Synonyms | PMPA (NAALADase inhibitor); 2-(Phosphonomethyl)pentane-1,5-dioic Acid |
| Molecular Formula | C₆H₁₁O₇P |
| Purity | ≥95% |
| Target | Carboxypeptidase |
| Solubility | Soluble to 100 mM in sterile water |
| Storage | Desiccate at RT |
| IUPAC Name | 2-(phosphonomethyl)pentanedioic acid |
| InChI | InChI=1S/C6H11O7P/c7-5(8)2-1-4(6(9)10)3-14(11,12)13/h4H,1-3H2,(H,7,8)(H,9,10)(H2,11,12,13) |
| InChIKey | ISEYJGQFXSTPMQ-UHFFFAOYSA-N |
| SMILES | C(CC(=O)O)C(CP(=O)(O)O)C(=O)O |
| Reference | </br>1:Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA). Rais R, Rojas C, Wozniak K, Wu Y, Zhao M, Tsukamoto T, Rudek MA, Slusher BS.J Pharm Biomed Anal. 2014 Jan;88:162-9. doi: 10.1016/j.jpba.2013.08.028. Epub 2013 Aug 30. PMID: 24055700 Free PMC Article</br>2:Radiofluorinated derivatives of 2-(phosphonomethyl)pentanedioic acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging of prostate cancer. Graham K, Lesche R, Gromov AV, Böhnke N, Schäfer M, Hassfeld J, Dinkelborg L, Kettschau G.J Med Chem. 2012 Nov 26;55(22):9510-20. doi: 10.1021/jm300710j. Epub 2012 Oct 24. PMID: 23025786 </br>3:2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. Luszczki JJ, Mohamed M, Czuczwar SJ.Eur J Pharmacol. 2006 Feb 15;531(1-3):66-73. Epub 2006 Jan 3. PMID: 16403497 </br>4:Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. Chen SR, Wozniak KM, Slusher BS, Pan HL.J Pharmacol Exp Ther. 2002 Feb;300(2):662-7. PMID: 11805230 Free Article |
